Skip Navigation LinksHome > September 2012 - Volume 37 - Issue 9 > Metastatic Neuroendocrine Carcinoma Presenting as a “Supersc...
Clinical Nuclear Medicine:
doi: 10.1097/RLU.0b013e31825b1e6c
Interesting Images

Metastatic Neuroendocrine Carcinoma Presenting as a “Superscan” on 68Ga-DOTANOC Somatostatin Receptor PET/CT

Naswa, Niraj; Karunanithi, Sellam; Soundararajan, Ramya; Das, Kalpa Jyoti; Agarwal, Krishan Kant; Malhotra, Arun; Bal, Chandrasekhar; Kumar, Rakesh MD

Free Access
Article Outline
Collapse Box

Author Information

From the Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.

Received for publication December 17, 2011; revision accepted April 12, 2012.

Conflicts of interest and sources of funding: none declared.

Reprints: Rakesh Kumar, MD, Department of Nuclear Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi-110029, Indica. E-mail: rkphulia@yahoo.com.

Collapse Box

Abstract

Abstract: PET/CT imaging using 68Ga-labeled somatostatin analogs has become a popular noninvasive diagnostic modality in the workup of patients with neuroendocrine tumors. A 65-year-old man with pancreatic neuroendocrine tumor with confirmed liver metastases on conventional imaging underwent restaging 68Ga-DOTANOC PET/CT to monitor response to cold octreotide therapy. Previous PET/CT had shown presence of multiple liver and skeletal metastases along with a primary pancreatic tumor showing intense tracer uptake. The present PET/CT study showed an increase in number and uptake of the metastatic lesions suggestive of progressive disease resulting in the appearance of a superscan.

Figure 1
Figure 1
Image Tools
Back to Top | Article Outline

REFERENCES

Figure 2
Figure 2
Image Tools
1. Lamberts SWJ, Krenning E, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrinol Rev. 1991: 12: 450–482.

2. Bombardieri E, Ambrosini V, Aktolun C, et al.. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010; 37: 1441–1448.

3. Virgolini I, Ambrosini V, Bomanji JB, et al.. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010; 37: 2004–2010.

4. Haug AR, Rominger A, Mustafa M, et al.. Treatment with octreotide does not reduce tumor uptake of 68Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med. 2011; 52: 1679–1683.

5. Kim SE, Kim DY, Lee DS, et al.. Absent of faint renal uptake in bone scan etiology and significance in metastatic bone disease. Clin Nucl Med. 1991; 16: 545–549.

6. Hain SF, Fogelman I. Nuclear medicine studies in metabolic bone disease. Semin Muskuloskelet Radiol. 2002; 6: 323–329.

7. Kim DW, Kim CG, Park SA, et al.. Metabolic super scan in 18F-FDG PET/CT imaging. J Korean Med Sci. 2010; 25: 1256–1257.

8. Liu RS, Chu YK, Chu LS, et al.. Superscan in patients with nasopharyngeal carcinoma. Clin Nucl Med. 1996; 21: 302–306.

Cited By:

This article has been cited 1 time(s).

Molecular Imaging and Biology
Effects of Chelator Modifications on Ga-68-Labeled [Tyr(3)]Octreotide Conjugates
Lin, M; Welch, MJ; Lapi, SE
Molecular Imaging and Biology, 15(5): 606-613.
10.1007/s11307-013-0627-x
CrossRef
Back to Top | Article Outline
Keywords:

neuroendocrine tumor; 68Ga-DOTANOC; PET/CT; superscan

© 2012 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.